Skip to main content
Public beta This website is in public beta – please give your feedback.

Example clinical scenario

You review a newborn with congenital heart disease. Tetralogy of Fallot was detected at the 20-week gestation scan, he was born small for gestational age and has a cleft palate. There is a family history of learning difficulties: his mother required extra help at mainstream school, leaving at the age of 16 with few qualifications.

When to consider genomic testing

Genomic testing should be considered if:

  • there is a family history of congenital structural heart disease or learning difficulties;
  • the patient has one of the congenital heart anomalies known to be associated with syndromic diagnoses – specifically tetralogy of Fallot, interrupted aortic arch and truncus arteriosus;
  • the patient has any form of congenital heart disease together with a cleft palate and/or disorder of calcium homeostasis; and/or
  • there is a complex or syndromic presentation, for example with other congenital malformations, dysmorphism, growth restriction or microcephaly.

In some cases, the presence of congenital heart disease may indicate a specific syndrome, some of which are listed below.

What do you need to do?

  • Consult the National Genomic Test Directory. From here you can access the rare and inherited disease eligibility criteria, which provides information about individual tests and their associated eligibility criteria. You can also access a spreadsheet containing details of all available tests.
  • To find out which genes are included on different gene panels, see the NHS Genomic Medicine Service (GMS) Signed Off Panels Resource.
  • Decide which of the panels best suits the needs of your patient or family. Congenital heart disease can be caused by either a chromosome anomaly or a gene single anomaly. If none of the specific conditions listed above are suspected, consider the following.
    • R137 Congenital heart disease (microarray). This should be considered if you want to investigate the chromosomes but do not want to sequence individual genes.
    • R27 Paediatric disorders. This should be considered if there is developmental delay or intellectual disability in association with congenital malformation or overgrowth, and you would like to investigate chromosomal and single gene causes. The test includes microarray and a whole genome sequencing (WGS) ‘super panel’ (a panel comprised of several different constituent panels forming one large panel).
  • For tests that are undertaken using WGS, including R27, you will need to:
    • submit parental samples alongside the child’s sample (this is trio testing) to aid interpretation, especially for the larger WGS panels (where this is not possible, for example because the child is in care or the parents are unavailable for testing, the child may be submitted as a singleton).
  • For tests that do not include WGS, including R137:
    • parental samples may be needed for interpretation of the child’s result. Parental samples can be taken alongside that of the child, and their DNA stored, or can be requested at a later date if needed.
  • The majority of tests are DNA based, and an EDTA sample (purple-topped tube) is required. Exceptions include karyotype testing and DNA repair defect testing (for chromosome breakage), which require lithium heparin (green-topped tube).
  • R27 is a large WGS super panel, and requesting it currently requires authorisation from clinical genetics services.
  • Information about patient eligibility and test indications was correct at the time of writing. When requesting a test, please refer to the National Genomic Test Directory to confirm the right test for your patient.

Resources

For clinicians

References:

↑ Back to top
  • Last reviewed: 05/04/2024
  • Next review due: 05/04/2025
  • Authors: Professor Kate Tatton-Brown
  • Reviewers: Dr Amy Frost, Dr Ellie Hay, Dr Emile Hendriks, Dr Hannah Massey, Dr Chinthika Piyasena